AML-related vs CH-type genetic abnormalities
| AML-related genetic abnormalities . | CH-type genetic abnormalities . |
|---|---|
| • Often occur later in the mutation hierarchy; may be the sole detected genetic event | • Occur earlier in the mutation hierarchy, often at higher VAF in comparison to AML-related genetic abnormalities |
| • Reduction in VAF or clearance associated with a reduction in the blast percentage after therapy | • Often persist in CR, usually at similar VAF to the pretherapy disease |
| • Reappearance of genetic abnormality in relapsed disease | • Persistence in relapsed disease |
| • Presence in CR associated with increased risk of relapse | • Presence in CR may not be associated with increased risk of relapse |
| • Eliminated following successful HCT | • Eliminated following successful HCT |
| AML-related genetic abnormalities . | CH-type genetic abnormalities . |
|---|---|
| • Often occur later in the mutation hierarchy; may be the sole detected genetic event | • Occur earlier in the mutation hierarchy, often at higher VAF in comparison to AML-related genetic abnormalities |
| • Reduction in VAF or clearance associated with a reduction in the blast percentage after therapy | • Often persist in CR, usually at similar VAF to the pretherapy disease |
| • Reappearance of genetic abnormality in relapsed disease | • Persistence in relapsed disease |
| • Presence in CR associated with increased risk of relapse | • Presence in CR may not be associated with increased risk of relapse |
| • Eliminated following successful HCT | • Eliminated following successful HCT |